Physician profile
Mandy Miranda
NPI 1801472824
$5,621.18
in general payments reported to CMS, 2019-2025
51 companies · $2,937 in 2025
The $2,937 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $570 · 2023: $890 · 2024: $1,225 · 2025: $2,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543 · Education: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.63 |
| Education | $508.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $558.45 | 2022-2025 | |
| Janssen Biotech, INC. | $446.39 | 2022-2025 | Talvey, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $392.76 | 2022-2025 | |
| Seagen INC. | $366.19 | 2022-2025 | Tukysa, Adcetris, Tivdak |
| Incyte Corporation | $345.10 | 2023-2025 | Monjuvi, Zynyz, Jakafi |
| Merck Sharp & Dohme LLC | $337.72 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $307.37 | 2024-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $222.53 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Astellas Pharma US INC | $179.14 | 2023-2025 | Xtandi, Padcev |
| Eisai INC. | $162.95 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $158.26 | 2023-2025 | Libtayo, Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $157.17 | 2022-2025 | Opdivo, Krazati, Opdualag |
| Glaxosmithkline, LLC. | $137.62 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $132.97 | 2023-2025 | |
| Puma Biotechnology, INC. | $109.22 | 2022-2025 | Nerlynx |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $107.31 | 2023-2025 | Enhertu, Datroway |
| Genzyme Corporation | $98.75 | 2025 | |
| Geron Corporation | $87.47 | 2025 | Rytelo |
| Myriad Genetic Laboratories, INC. | $79.18 | 2022-2024 | Myrisk |
| Kite Pharma, INC. | $76.30 | 2025 | Yescarta |
| Sumitomo Pharma America, INC. | $72.04 | 2023-2025 | Orgovyx |
| Emd Serono, INC. | $71.54 | 2024-2025 | |
| Legend Biotech USA INC. | $71.44 | 2024-2025 | Carvykti |
| Aveo Pharmaceuticals, INC. | $64.65 | 2022-2025 | Fotivda |
| Sobi, INC | $60.63 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $59.60 | 2023-2024 | Onivyde, Somatuline Depot |
| Kyowa Kirin, INC. | $59.59 | 2025 | |
| Lilly USA, LLC | $54.69 | 2022-2025 | Verzenio, Jaypirca |
| Agios Pharmaceuticals, INC. | $53.34 | 2024-2025 | Pyrukynd |
| Amgen INC. | $51.76 | 2022-2025 | Kyprolis, Lumakras |
| Array Biopharma INC | $50.60 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Abbvie INC. | $45.19 | 2025 | |
| G1 Therapeutics, INC. | $39.18 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $38.49 | 2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $34.28 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $32.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.28 | 2025 | Fruzaqla |
| Csl Behring | $30.08 | 2024 | Afstyla, Idelvion |
| Blueprint Medicines Corporation | $28.75 | 2022 | |
| Mirati Therapeutics, INC. | $23.87 | 2024 | Krazati |
| Genentech USA, INC. | $21.77 | 2022 | |
| Adc Therapeutics America, INC. | $20.64 | 2024 | |
| Stemline Therapeutics INC. | $17.88 | 2025 | Orserdu |
| Karyopharm Therapeutics INC. | $17.54 | 2023 | Xpovio |
| Macrogenics, INC. | $17.26 | 2023 | |
| Cti Biopharma Corp. | $16.89 | 2023 | Vonjo |
| Servier Pharmaceuticals LLC | $16.53 | 2025 | |
| Myovant Sciences INC. | $16.06 | 2022 | |
| Exelixis INC. | $15.15 | 2023 | Cabometyx |
| Syndax Pharmaceuticals, INC. | $14.28 | 2025 | |
| Rare Disease Therapeutics, INC. | $11.87 | 2023 | Anavip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.